LBA2 TALENTACE: A phase III, open-label, randomized study of on-demand transarterial chemoembolization (TACE) combined with atezolizumab + bevacizumab (Atezo+Bev) or on-demand TACE alone in patients with systemically untreated, intermediate-to-high burden unresectable hepatocellular carcinoma (uHCC)

作者：Jiahong Dong, Guangsen Han, Satoshi Ogasawara, Ran Liu, Shanzhi Gu, Fang Liu, M. Zhao, Hao Hu, Zongwen Liu, Kezhi Lin, Junjie Liu, Zhenhua Lin, Yaojun Zhang, Tingting Peng, Junying Song, Makoto Ueno, Jie Zhu, Bai Li, Y. Shi, M. Kudo · 发表于：Annals of Oncology · 年份：2025 · DOI：10.1016/j.annonc.2025.05.542 · 被引用次数：37 · 研究领域：Hepatocellular Carcinoma Treatment and Prognosis、Liver physiology and pathology、Cancer Mechanisms and Therapy